Oct 31, 2018
Usually, only 1 question is asked from New Drugs in competitive exams like AIIMS, PGI, NEET. Only JIPMER is one such exam where many questions are asked from this topic.
Pharmacology expert, Dr. Gobind Rai Garg advises doing this topic in the end. He says, if you are not particularly preparing for JIPMER exam, try to do this topic of new drugs only if you have already completed the syllabus of Pharmacology. So, don’t waste your time unless you have completed the basics of Pharmacology.
Below is a comprehensive list of new drugs approved in 2018. The table includes the name of the drug, mechanism, route and indication.
Drug | Mechanism | Route | Indication |
Andexanet alpha | Bind to Factor Xa inhibitors | Intravenous | To reverse overdose of rivaroxaban and apixaban |
Apalutamide | Andreogen receptor antagonist | Oral | Prostate carcinoma |
Avatrombopag | Thrombopoietin receptor agonist | Oral | Thrombocytopenia in patients with chronic liver disease |
Baloxavirmarboxil | Inhibit viral replication by inhibiting Cap-dependent endonuclease activity of viral polymerase | Oral | Single dose treatment of Acute uncomplicated influenza |
Baricitinib | Janus Kinase inhibitor | Oral | Rheumatoid Arthritis |
Bictegravir | Integrase inhibitor | Oral | HIV |
Binimetinib | MET tyrosine kinase inhibitor | Oral | BRAF V600E or V600K mutation-positive malignant melanoma |
Burosumab | Monoclonal antibody against FGF-23 | Subcutaneous | X-linked hypophosphatemia |
Cannabidiol | Unknown | Oral | Lennox Gastaut syndrome Dravet Syndrome |
Cemiplimab | Monoclonal antibody against Programmed Death receptor (PD-1) | Intravenous | Squamous cell carcinoma of skin |
Cenegermin | Recombinant human nerve growth factor | Eye drops | Neurotrophic keratitis |
Dacomitinib | EGFR tyrosine kinase inhibitor | Oral | Non-small cell lung cancer with EGFR exon 19 deletion or exon 21 L858R substitution mutations |
Doravirine | Non-nucleoside Reverse Transcriptase Inhibitor | Oral | HIV |
Duvelisib
| Inhibitor of PI-3 kinase gamma and delta | Oral | Small lymphocytic lymphoma Follicular lymphoma Chronic lymphoid leukemia |
Elagolix
| GnRH antagonist | Oral | Pain associated with endometriosis |
Elapegademase | Recombinant Adenosine deaminase enzyme | Intramuscular | Adenosine Deaminase-Severe Combined Immunodeficiency |
Encorafenib
| BRAF-Kinase Inhibitor | Oral | BRAF V600E or V600K mutation-positive malignant melanoma |
Eravacycline
| Inhibit protein synthesis like other tetracyclines | Intravenous | Complicated intra-abdominal infections |
Erenumab | Monoclonal antibody against CGRP | Sc | Migraine prophylaxis |
Fostamatinib disodium hexahydrate | Spleen tyrosine kinase inhibitor | Oral | ITP |
Fremanezumab
| Monoclonal antibody against CGRP | Subcutaneous | Migraine prophylaxis |
Galcanezumab | Monoclonal antibody against CGRP | Subcutaneous | Migraine prophylaxis |
Ibalizumab | MAb against CD4 | Iv | HIV |
Inotersen | Antisense oligonucleotide against transthyretin mRNA | Subcutaneous | Polyneuropathy of hereditary transthyretin-mediated amyloidosis |
Ivosidenib
| Isocitrate dehydrogenase 2 (IDH2) inhibitor | Oral | Acute myeloid leukemia with IDH2 mutation |
Lanadelumab
| Monoclonal antibody against plasma kallikrein | Subcutaneous | Hereditary Angioneurotic Edema |
Lofexidine | Alpha 2 agonist | Oral | To decrease opioid withdrawal symptoms |
Lusutrombopag | Thrombopoietin receptor agonist | Oral | Thrombocytopenia in patients with chronic liver disease |
Lutetium lu 177 dotatate
| Peptide receptor radionuclide therapy | Intravenous | Gastro-entero-pancreatic neuroendocrine tumors |
Megalastat
| Pharmacological chaperone for Alpha galactosidase | Oral | Fabry’s disease |
Mogamulizumab
| Monoclonal antibody against CCR-4 | Intravenous | Mycosis fungoides Sezary syndrome |
Moxetumomabpasudutox
| Monoclonal antibody against CD22 conjugated with Pseudomonas exotoxin | Intravenous | Hairy cell leukemia |
Moxidectin
| Bind to Glutamate and GABA chloride channels | Oral | Onchocerciasis |
Omadacycline
| Inhibit protein synthesis like other tetracyclines | Oral Intravenous | Community acquired bacterial pneumonia Acute skin and skin structure infections |
Patisiran
| Small Interfering RNA based therapy against mutant transthyretin | Intravenous | Polyneuropathy in patients with transthyretin mediated amyloidosis |
Pegvailase | Substitute of Phenylalanine hydroxylase | Sc | Phenylketonuria |
Plazomicin
| Inhibit protein synthesis like other aminoglycosides | Intravenous | Complicated UTI |
Sarecycline
| Inhibit protein synthesis like other tetracyclines | Oral | Inflammatory lesions of non-nodular moderate to severe acne |
Segesterone + ethinyl estradiol | Inhibit ovulation | Vaginal ring | Contraception (once yearly) |
Sodium zirconium cyclosilicate | Binds to K and increase fecal excretion | oral | Hyperkalemia |
Stiripentol
| Increases GABAergic activity | Oral | Dravet Syndrome |
Talazoparib | PARP inhibitor | Oral | breast cancer with a germline BRCA mutation |
Tecovirimat
| Inhibit formation of extracellular viral forms | Oral | Small pox |
Tefenaquine
| Free radical mediated killing of hypnozooites | Oral | Single dose radical cure of P. vivax malaria |
Tildrakizumab | MAb against IL-23 | Sc | Plaque Psoriasis |
Tizacaftor + ivacaftor | CFTR stimulator and potentiator | Oral | Cystic fibrosis |
Tolvaptan | Vasopressin V2 receptor antagonist | Oral | To slow kidney function decline in adult polycystic kidney disease |
For more such mnemonics on new drugs download the "Pharmacology by Dr. Gobind Rai Garg" app.
For Android- Click Here
For iOS - Click Here
To go through the detailed video discussion on:
'New Drugs Approved in 2018'- Click Here
'New Drugs Approved in 2017'- Click Here
Good Luck!
Keep Following PrepLadder for more updates!!
If you’re having trouble understanding congestive heart failure, then you have landed on the right page. Here we will discuss everything you need to know about conges
Dermatology, Psychiatry, Anesthesia and Radiology are the minor subjects of Prof 4 that, if prepared effectively, can boost the exam score. To help students prepare f
PrepLadder always strives to enrich your learning experience with best-in-class preparation resources.
Continuing with this legacy of providing our student